Envista (NYSE:NVST – Get Free Report) was upgraded by equities researchers at Leerink Partnrs from a “strong sell” rating to a “hold” rating in a research note issued to investors on Thursday, Zacks.com reports. Leerink Partnrs also issued estimates for Envista’s FY2024 earnings at $0.70 EPS, Q1 2025 earnings at $0.22 EPS, Q2 2025 earnings at $0.22 EPS, Q3 2025 earnings at $0.30 EPS, Q4 2025 earnings at $0.32 EPS and FY2026 earnings at $1.28 EPS.
NVST has been the subject of several other reports. Wells Fargo & Company began coverage on shares of Envista in a report on Tuesday, October 8th. They issued an “equal weight” rating and a $20.00 price objective for the company. JPMorgan Chase & Co. lowered shares of Envista from an “overweight” rating to a “neutral” rating and lowered their price objective for the stock from $23.00 to $16.00 in a report on Thursday, August 8th. Needham & Company LLC reiterated a “hold” rating on shares of Envista in a report on Thursday. Evercore ISI lifted their price target on Envista from $18.00 to $23.00 and gave the company an “outperform” rating in a research report on Monday, September 23rd. Finally, Robert W. Baird increased their price objective on Envista from $17.00 to $22.00 and gave the stock a “neutral” rating in a report on Thursday. One investment analyst has rated the stock with a sell rating, eleven have issued a hold rating and three have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $20.71.
Read Our Latest Stock Report on Envista
Envista Stock Up 9.0 %
Envista (NYSE:NVST – Get Free Report) last issued its quarterly earnings data on Wednesday, October 30th. The company reported $0.12 earnings per share for the quarter, topping analysts’ consensus estimates of $0.09 by $0.03. Envista had a positive return on equity of 3.59% and a negative net margin of 53.42%. The firm had revenue of $601.00 million for the quarter, compared to analyst estimates of $590.34 million. During the same period last year, the company earned $0.43 EPS. The business’s quarterly revenue was down 4.8% compared to the same quarter last year. Sell-side analysts forecast that Envista will post 0.69 earnings per share for the current year.
Insider Transactions at Envista
In other Envista news, CFO Eric D. Hammes acquired 24,532 shares of Envista stock in a transaction that occurred on Monday, August 12th. The stock was bought at an average cost of $16.33 per share, for a total transaction of $400,607.56. Following the acquisition, the chief financial officer now owns 24,532 shares of the company’s stock, valued at $400,607.56. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink. Company insiders own 1.30% of the company’s stock.
Institutional Trading of Envista
Several large investors have recently modified their holdings of NVST. Tweedy Browne Co LLC bought a new stake in shares of Envista during the 1st quarter valued at about $21,053,000. SG Americas Securities LLC increased its holdings in Envista by 3,271.2% during the first quarter. SG Americas Securities LLC now owns 144,522 shares of the company’s stock valued at $3,090,000 after buying an additional 140,235 shares during the last quarter. M&G Plc raised its position in Envista by 12.5% in the second quarter. M&G Plc now owns 306,253 shares of the company’s stock worth $5,206,000 after acquiring an additional 33,923 shares during the period. Duality Advisers LP purchased a new position in shares of Envista during the 1st quarter worth $1,903,000. Finally, Harbor Capital Advisors Inc. grew its position in shares of Envista by 287.4% during the 2nd quarter. Harbor Capital Advisors Inc. now owns 169,648 shares of the company’s stock valued at $2,821,000 after acquiring an additional 125,861 shares during the period.
Envista Company Profile
Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.
See Also
- Five stocks we like better than Envista
- 3 REITs to Buy and Hold for the Long Term
- Top 3 REIT Picks for 2025: High Yields and Rising Earnings Ahead
- How to Evaluate a Stock Before BuyingÂ
- 3 Stocks Well Below 52-Week Highs With Strong Growth Projections
- CD Calculator: Certificate of Deposit Calculator
- 3 Chip Stocks Expected to See Accelerating Sales Growth
Receive News & Ratings for Envista Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Envista and related companies with MarketBeat.com's FREE daily email newsletter.